This first-in-human study of Halo Therapeutics respiratory antiviral spray for coronaviruses will investigate the safety and tolerability of the treatment prior to subsequent studies being conducted in patients that are SARS-CoV-2 positive or are at risk of becoming SARS-CoV-2 positive.
Based on world-class research carried out at Bristol, Halo Therapeutics was established as a spin-out company in 2020 by CEO Dr Daniel Fitzgerald, Professor Christiane Schaffitzel, and Professor Imre Berger.
"Due to a large portion of the unvaccinated, and the waning efficacy of the vaccines, we still see a high incidence and morbidity of COVID-19 infections, as well as a growing number of long Covid patients.
"Halo's antiviral spray will be the best prevention against being infected by new mutant strains, which continue to spread globally. We need to be better prepared for the next waves of Covid this time."